Pain perception can be effectively controlled by neurotransmitters that operate in the CNS. This modulation has been well characterized in the dorsal horn of the spinal cord, where impulses carried by nociceptive (pain sensing) fibers are processed before they are transmitted to the brain. In addition to these central mechanisms, intrinsic control of pain transmission can occur at terminals of afferent nerve fibers outside of the CNS. One prominent example of peripheral regulation is provided by the endogenous opioids, which are released from activated immune cells during inflammation and inhibit pain initiation by interacting with opioid receptors that are localized on sensory nerve endings 1 .
Endocannabinoid mediators might serve a function analogous to that of the opioids, as pharmacological activation of peripheral CB 1 and CB 2 cannabinoid receptors inhibits pain-related behaviors [2] [3] [4] [5] , whereas genetic disruption of CB 1 receptor expression in primary nociceptive neurons exacerbates such behaviors 6 . Moreover, there is evidence that clinical conditions associated with neuropathic pain or inflammation are accompanied by peripheral elevations in the levels of the endocannabinoid anandamide (for example, complex regional pain syndrome and arthritis) 7, 8 . Another major endocannabinoid transmitter, 2-arachidonoylglycerol, has also been implicated in nociceptive signaling outside of the CNS 6, 9 .
Although these findings suggest that the endocannabinoid system is important for the peripheral regulation of nociception, they offer no definitive insight on the identity of the endogenous ligand or ligands involved in this function. Filling this gap is essential for defining the molecular underpinnings of intrinsic mechanisms controlling pain initiation and for developing new analgesic agents devoid of unwanted central effects. We discovered a potent brain-impenetrant inhibitor of the anandamide-degrading enzyme FAAH and used this drug to magnify the actions of peripheral anandamide and unmask its possible role in the control of pain initiation 10 .
RESULTS

Discovery of a peripherally restricted FAAH inhibitor
Current FAAH inhibitors readily cross the blood-brain barrier 10 . To produce inhibitors with restricted access to the CNS, we added chemical groups of varying polarity to the proximal phenyl ring of the brainpermeant O-arylcarbamate URB597 (Table 1, compound 1) 11, 12 in a position in which small-sized hydrophilic substituents are not expected to impair biological activity 13 . The new compounds had comparable potencies when tested in membrane preparations of rat brain FAAH and were equally effective at blocking liver FAAH activity when administered systemically in mice (1 mg per kg of body weight, intraperitoneal; Table 1 , compounds 2-6). The compounds markedly differed, however, in their ability to access the CNS. In particular, the p-hydroxyphenyl derivative URB937 ( Table 1 , compound 2) suppressed FAAH activity in peripheral tissues of mice and rats, but failed to affect FAAH activity in the brain ( Table 1 and Supplementary  Table 1) . A dose-exploration study in mice indicated that the median Peripheral cannabinoid receptors exert a powerful inhibitory control over pain initiation, but the endocannabinoid signal that normally engages this intrinsic analgesic mechanism is unknown. To address this question, we developed a peripherally restricted inhibitor (URB937) of fatty acid amide hydrolase (FAAH), the enzyme responsible for the degradation of the endocannabinoid anandamide. URB937 suppressed FAAH activity and increased anandamide levels outside the rodent CNS. Despite its inability to access brain and spinal cord, URB937 attenuated behavioral responses indicative of persistent pain in rodent models of peripheral nerve injury and inflammation and prevented noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CB 1 cannabinoid receptor blockade prevented these effects. These results suggest that anandamide-mediated signaling at peripheral CB 1 receptors controls the access of pain-related inputs to the CNS. Brainimpenetrant FAAH inhibitors, which strengthen this gating mechanism, might offer a new approach to pain therapy. 1 2 6 6 VOLUME 13 | NUMBER 10 | OCTOBER 2010 nature neurOSCIenCe a r t I C l e S effective dose (ED 50 ) of URB937 for FAAH inhibition in brain (40 mg per kg, subcutaneous) was 200-fold higher than the ED 50 for FAAH inhibition in liver (0.2 mg per kg, subcutaneous) (Fig. 1a) . Moreover, URB937 (1 mg per kg, intraperitoneal) distributed rapidly in blood and liver after systemic administration, but remained undetectable in brain tissue (Fig. 1b) . As seen with other O-arylcarbamates, which are known to interact with FAAH through a covalent mechanism 11,14 , URB937's inhibition of peripheral FAAH activity in vivo was both rapid and lasting (Supplementary Fig. 1) .
Because of its lipophilicity, URB937 should passively diffuse into the CNS unless diffusion is actively countered (distribution coefficient, LogD oct,pH 7.4 : URB937, 3.03 ± 0.01; CNS-penetrant inhibitor URB597, 3.71 ± 0.01; mean ± s.e.m.; n = 3). To test these alternative possibilities, we determined the permeability and efflux ratios of URB937 through polarized monolayers of human epithelial TC7 cells, which express various protein transporters involved in the extrusion of drugs from the brain 15 . URB937 did not equally distribute across the apical and basal compartments of TC7 monolayers, as would be expected of a lipophilic molecule moving by passive diffusion. Instead, the compound accumulated into the apical compartment (permeability (% recovery): apical-basal, 38 nm s −1 (83%); basal-apical, 371 nm s −1 (95%); efflux ratio, 9.8; mean of two independent experiments). This result suggests that URB937 is extruded from the CNS. Supporting this interpretation, injection of URB937 into the lateral cerebral ventricles of rats (0.01-0.1 mg per kg) was followed by the appearance of the compound in peripheral blood (Fig. 1c) and concurrent inhibition of FAAH activity in liver (Fig. 1d) . Conversely, systemic administration of a 250-fold higher dose of URB937 (25 mg per kg, intraperitoneal) had no effect on brain FAAH activity, which was markedly reduced by a low dose of the CNS-penetrant inhibitor URB597 (1 mg per kg, intraperitoneal) (Fig. 1e) .
To gain insight into the transport mechanism involved in the extrusion of URB937 from the CNS, we administered various inhibitors of drug transport across the blood-brain barrier, along with a high systemic dose of URB937 that did not achieve brain penetration (25 mg per kg, intraperitoneal). Treatment with Ko-143 (10 mg per kg, intraperitoneal), an inhibitor of the ATP-binding cassette transporter breast cancer resistance protein (BCRP) 15 , markedly increased access of URB937 to the brain (Fig. 1e) . A similar effect was obtained with 2,6-dichloro-4-nitrophenol, which blocks the sulfate conjugation required for BCRP-mediated transport of xenobiotics 16 (Fig. 1e) . In contrast, administration of other drug-transport inhibitors, including verapamil, probenecid and rifampicin 15 , was ineffective (Fig. 1e) . The results suggest that URB937 is exported from the CNS by a transport system that is pharmacologically indistinguishable from BCRP. The molecular identification of this system will require additional experimentation.
Administration of URB937 (1 mg per kg, intraperitoneal) in mice increased anandamide levels in peripheral tissues, but not in forebrain or hypothalamus ( Fig. 1f and Supplementary Fig. 2 ). This effect was caused by selective inhibition of FAAH activity, as the effect was accompanied by elevations of other FAAH substrates, such as palmitoylethanolamide (PEA 17 ; Fig. 1f) , and it was not seen in mutant FAAH-deficient mice 18 (Fig. 1g) . Notably, URB937 did not affect monoacylglycerol lipase activity in vitro (median inhibitory concentration > 100 μM, n = 3) or alter tissue levels of its endocannabinoid substrate, 2-arachidonoylglycerol, in vivo ( Supplementary Fig. 2 ). a r t I C l e S Modulation of visceral pain Current FAAH inhibitors attenuate behavioral responses to noxious stimuli in rodents, a property that is generally attributed to their ability to augment anandamide signaling in brain and spinal cord 10, 11 . To test whether peripheral anandamide contributes to these actions, we examined the effects of URB937 on nocifensive responses evoked by acetic acid injection into the peritoneal cavity of mice. Subcutaneous administration of URB937 reduced acetic acidinduced writhing with an ED 50 of 0.1 mg per kg (Fig. 2a and data not shown). This effect was comparable in efficacy to those elicited by the CNS-penetrant FAAH inhibitor URB597 and the cyclooxygenase inhibitor indomethacin (each at 1 mg per kg, subcutaneous; Fig. 2a) , correlated with the degree of peripheral FAAH inhibition (Pearson correlation coefficient, r = 0.96; Fig. 2b) , and was absent in mutant FAAH-deficient mice compared with their wild-type littermates (Fig. 2c) . The antinociceptive effect of URB937 was blocked by the selective CB 1 antagonists rimonabant and AM251, but not by the CB 2 antagonist AM630 (each at 1 mg per kg, subcutaneous; Fig. 2d ). Although anandamide can activate vanilloid type 1 transient receptor potential (TRPV-1) channels 19 , URB937 evoked no detectable nocifensive behavior when administered alone (Fig. 2a) , which suggests that the tissue concentrations reached by endogenous anandamide following peripheral FAAH inhibition are insufficient to engage TRPV-1.
Treatment with URB937 elevated tissue levels of PEA (Fig. 1f) , a peroxisome proliferator-activated receptor α (PPAR-α) agonist that acts synergistically with anandamide to attenuate pain responses in rodents 2, 20, 21 . Co-administration of the PPAR-α antagonist MK886 (1 mg per kg, subcutaneous) or genetic disruption of PPAR-α prevented the effects of URB937 in mice (Fig. 2d,e) . We interpret these findings to indicate that URB937 inhibits acetic acid-induced pain responses through a mechanism that requires both anandamide-dependent activation of CB 1 receptors and PEA-dependent activation of PPAR-α.
Modulation of neuropathic and inflammatory pain
We next asked whether URB937 might influence persistent pain caused by nerve damage or inflammation. We produced peripheral nerve injury in mice by loosely tying the left sciatic nerve 22 . A single dose of URB937 (1 mg per kg, intraperitoneal, 2 h before testing), administered 1 week after surgery, attenuated thermal hyperalgesia and suppressed mechanical hyperalgesia and mechanical allodynia on the operated side (Fig. 3a-c) . Notably, this response was not accompanied by changes in the reactivity to cutaneous stimuli applied to the non-operated side, indicating that URB937 normalized mechanical , prevented the effects of URB937 on mechanical hyperalgesia (g), thermal hyperalgesia (h) and mechanical allodynia (i). Results are expressed as mean ± s.e.m. (n = 6 in each panel). *P < 0.05, **P < 0.01 and ***P < 0.001 versus baseline; # P < 0.05, ## P < 0.01 and ### P < 0.001 versus vehicle. a r t I C l e S and thermal thresholds altered by nerve injury, rather than exerting a generalized antinociceptive action (Fig. 3a-c ). This conclusion was further supported by the lack of activity of URB937 in the hot-plate test (Supplementary Fig. 3 ). As previously seen for URB597 (ref. 23 ), subchronic treatment with URB937 (1 mg per kg, intraperitoneal) once a day for 7 d, starting 3 d after nerve ligation, elicited a set of analgesic effects that were indistinguishable from those caused by single drug dosing (Fig. 3d-f) . Moreover, such effects were completely blocked by rimonabant, but not by AM630 (Fig. 3g-i) or MK886 (each at 1 mg per kg, subcutaneous; Supplementary Fig. 4) .
In another group of mice, we induced peripheral inflammation by injecting the polysaccharide carrageenan into one of the hind paws. This resulted in the development of mechanical and thermal hyperalgesia as well as local edema (Fig. 4) . A single systemic injection of URB937 (1 mg per kg, intraperitoneal), administered at the same time as carrageenan, decreased mechanical and thermal hyperalgesia, as assessed 4 and 24 h after carrageenan treatment (Fig. 4a,b) . URB937 also reduced mechanical allodynia measured 24 h after carrageenan treatment (Fig. 4c) . We obtained similar results when mice were treated with the CNS-permeant inhibitor URB597 (1 mg per kg, intraperitoneal; Supplementary Fig. 5 ). The antihyperalgesic effects of URB937 were restricted to the inflamed paws (Supplementary Fig. 6 ) and were prevented by rimonabant, but not by AM630 (Fig. 4a-c) or MK886 (Supplementary Fig. 7 ) (each at 1 mg per kg, intraperitoneal). Moreover, URB937 reversed paw edema 24 h after carrageenan injection via a mechanism that was sensitive to both CB 1 and CB 2 receptor blockade (Fig. 4d) . Subchronic treatment with URB937 (1 mg per kg, intraperitoneal, once a d for 3 d) was effective at inhibiting carrageenaninduced pain and edema (Supplementary Fig. 8 ). Together, these results indicate that URB937 alleviates neuropathic and inflammatory pain in mice via a mechanism that primarily depends on the activation of peripheral CB 1 receptors by locally produced anandamide. (1 mg per kg, intraperitoneal) , administered alone or in combination with rimonabant (R, 1 mg per kg, intraperitoneal) or AM630 (AM, 1 mg per kg, intraperitoneal) on carrageenan-induced responses to mechanical hyperalgesia (a), thermal hyperalgesia (b), mechanical allodynia (c) and paw edema (d). Mechanical and thermal hyperalgesia were measured immediately before carrageenan injection (0 h) or 4 h and 24 h after injection. Mechanical allodynia was measured 0 h and 24 h after carrageenan. Results are expressed as mean ± s.e.m. (n = 6). *P < 0.05, **P < 0.01 and ***P < 0.001 versus vehicle; # P < 0.05, ## P < 0.01 and ### P < 0.001 versus URB937. Results are expressed as mean ± s.e.m. (n = 5-7). *P < 0.05, all groups versus URB937; # P < 0.05, URB937 plus rimonabant or rimonabant alone versus URB937; **P < 0.05, vehicle or rimonabant alone versus URB937.
a r t I C l e S
Modulation of spinal nociceptive processing To determine whether URB937 alters the central processing of nociceptive inputs, we measured spinal cord expression of Fos protein, a marker of neuronal activity, in a model of persistent pain produced by administration of formalin into the dorsal hind paw of rats. Formalin elicited a marked nocifensive response, which was attenuated by co-injection of URB937 (1 mg per kg, intraperitoneal). The FAAH inhibitor reduced formalin-induced pain behavior relative to vehicle, the CB 1 antagonist rimonabant (2 mg per kg, intraperitoneal), or a combination of rimonabant and URB937 (Fig. 5a) . Further analyses revealed that URB937 decreased the area under the curve of formalin-induced pain behavior compared with all other treatment groups (Supplementary Fig. 9 ) and that this effect was a result of a reduction in the late phase (phase 2) of the formalin response ( Fig. 5b and Supplementary Fig. 9 ), during which ongoing primary afferent fiber activity is accompanied by inflammation and central sensitization of spinal nociceptive circuits 24, 25 . URB937 lowered the Fos response to formalin in spinal cord regions implicated in nociceptive processing (Fig. 5c-e) , namely the superficial (lamina I and II) and neck regions of the dorsal horn (lamina V and VI) (Fig. 5f) . To a lesser extent, URB937 also suppressed Fos protein expression in the nucleus proprius (lamina III and IV) and ventral horn (Fig. 5f) . These effects were prevented by the CB 1 antagonist rimonabant (2 mg per kg, intraperitoneal), which did not alter Fos levels when administered without URB937 (Fig. 5f) . The ability of URB937 to modulate spinal nociceptive processing, despite its lack of CNS penetration, suggests that peripheral FAAH inhibition attenuates pain-related inputs before they enter the spinal cord.
Cannabinoid receptor agonists stimulate feeding through both central and peripheral mechanisms 26 . In contrast, as was previously seen for the CNS-penetrant FAAH inhibitor URB597 (ref. 12), administration of URB937 (1 mg per kg, intraperitoneal, 30 min before dark) did not alter daily food intake, feeding pattern (latency to feed, meal frequency and satiety ratio) or spontaneous locomotor activity in mice (Supplementary Fig. 10 ). DISCUSSION URB937 is a potent FAAH inhibitor that does not readily enter the CNS and thus interrupts anandamide deactivation only in peripheral tissues. Despite this restricted range of action, URB937 caused marked antinociceptive effects in rodent models of acute and persistent pain, which were prevented by CB 1 cannabinoid receptor blockade. These findings suggest that inhibition of peripheral FAAH activity magnifies an endogenous analgesic mechanism, mediated by anandamide, that regulates the transmission of emerging pain signals to the spinal cord and the brain.
We hypothesize that peripheral anandamide acts as a diffuse paracrine signal to modulate the intensity of pain stimuli as they arise in damaged tissues. Two lines of evidence support this idea. First, signals generated by inflammation and neural injury can trigger the local production and release of anandamide. For example, membrane depolarization and activation of TRPV-1 channels each stimulates anandamide formation in cultures of sensory neurons 27 , whereas activation of Toll-like receptor 4 causes a similar effect in macrophages 28 . These signals, and likely others that remain to be identified, may contribute to the elevations in peripheral anandamide documented in animal models of spinal nerve injury and inflammation 6, 9 , as well as in painful human conditions such as complex regional pain syndrome 7 and arthritis 8 . Second, CB 1 receptors are broadly distributed throughout peripheral tissues and organs. In particular, they are expressed in primary sensory neurons of heterogeneous sizes and are transported to peripheral nerve endings 29, 30 . There, CB 1 receptor activation may be both necessary to maintain normal pain thresholds 6 and sufficient to exert marked antinociceptive effects 2, 4 . CB 1 receptors present on pain-sensing terminals may mediate the analgesic and anti-inflammatory actions of locally produced anandamide through their inhibitory influence on the release of excitatory neuropeptides 31 . Other receptors appear to contribute, along with CB 1 , to anandamide signaling in response to injury. Two candidates are CB 2 and PPAR-α, which are present in peripheral sensory neurons and immune cells, and act synergistically with CB 1 to reduce pain 2, 20, 21, 32, 33 . Our results suggest that CB 1 receptors cooperate with PPAR-α to modulate visceral pain in the acetic acid model and with CB 2 to reduce edema in the carrageenan model. Notably, however, CB 1 receptors appear to exclusively mediate the analgesic effects of URB937 in models of neuropathic and inflammatory pain.
Mutant mice in which FAAH expression is selectively disrupted in non-neuronal cells, but is preserved in peripheral and central neurons, have a phenotype in which normal nociceptive transmission is accompanied by reduced responsiveness to pro-inflammatory triggers 34 . A plausible explanation for this finding is that the signaling activity of anandamide at peripheral nociceptive neurons is influenced by FAAH localized to the nociceptors themselves, rather than to neighboring non-neural cells. This view is consistent with the observation that peripheral axotomy induces FAAH expression in large-sized sensory neurons of the dorsal root ganglia, a response that is expected to extend the co-localization of FAAH with CB 1 receptors and thus enhance the ability of this enzyme to terminate anandamide signaling 35 .
Direct activation of peripheral cannabinoid receptors causes profound analgesic effects in experimental models of pain 36, 37 , but is accompanied by psychotropic actions. Our findings indicate that a high degree of analgesia can also be obtained by magnifying the intrinsic activity of an anandamide-based signaling system involved in the dynamic regulation of nociceptive homeostasis outside of the CNS. These findings offer new insights into the intrinsic control of pain and might be exploited therapeutically to develop analgesic agents devoid of central side effects.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
